Equity intelligence report • June 27, 2026
AbbVie Inc. is facing significant financial hurdles as it sets aside $2 billion to settle over 3,000 lawsuits related to its opioid drug, coupled with lower sales forecasts following a second-quarter earnings miss. These developments, alongside pressures from proposed Medicare negotiations on drug prices, have contributed to a decline in its market capitalization by $13.2 billion. Despite efforts to bolster its portfolio with sales from newer drugs Skyrizi and Rinvoq and a recent commitment to expand U.S. manufacturing, the looming challenges surrounding Humira's waning market exclusivity and fluctuating stock performance continue to overshadow AbbVie's outlook.
Click a month on the chart to update the report below.
